NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Incorporated (OTCBB: ADXS), has updated survival data for its Phase I clinical trial (Trial) of its live Listeria vaccine ADXS11-001(formerly named Lovaxin-C) in the treatment of advanced, metastatic cervix patients who have failed first line cytotoxic therapy.
